february 2018 mass tort topics of interest · 2018-04-04 · benicar 5 taxotere 13 essure 19...

Mass Tort Topics of Interest February 2018

Created by Ethan HeckDirector of Business Development

Direct Line: (858) [email protected]

Table of Contents

Drug Injury Campaigns

Medical Device Injury Campaigns

Product Injury Campaigns

Abilify 3 PPIs 11 Attune Knee 17 Breast Implant 25

Actemra 4 Tasinga 12 Bair Hugger 18 Roundup 26

Benicar 5 Taxotere 13 Essure 19 Stöckert 3T 27

Gadolinium 6 TRT 14 Hernia Mesh 20 Talcum Powder 28

Invokana 7 Xarelto 15 IVC Filter 21

Limbrel 8 Zofran 16 Lfit V40 (Stryker) 22

Onglyza 9 Mirena - PTC 23

Opioids 10 Smith & Nephew 24

Abilify (aripiprazole)

Manufacturer: Bristol-Myers Squibb and Otsuka Pharmaceuticals

Issues/ injuries: Abilify is an antipsychotic prescribed to nearly a million Americans each year. Akin to the injuries of a previous pharmaceutical mass tort (Mirapex – MDL 1863), several studies have linked Abilify to compulsive behaviors such as binge eating, hypersexual behavior, compulsive shopping, and pathological gambling in people who have no history of these problems prior to taking the drug.

FDA Warning: On May 3, 2016 FDA issued a warning that aripiprazole, which is found in medications like Abilify and Aristada, has been linked to uncontrollable urges to eat, gamble, shop, and sex.

MDL 2734: Northern District of Florida under Judge M. Casey Rodgers. These claims have been fast tracked with first bellwether set to begin in June 2018. In January 2018 plaintiffs filed a motion to join claims for the bellwether trials. *Please call for criteria and pricing

Actemra (tocilizumba)

Manufacturer: Genetech (Roche subsidiary)

Issues: Rheumatoid and giant cell arthritis drug Actemra, an immunoresponsive drug (IL-6 receptor inhibitors) that was approved in 2010, has been linked to heart attacks, strokes, interstitial lung disease, heat failure, acute pancreatitis, and other life threatening complications.

June 2017: A report by Statesnews.com identified thousands of adverse event reports submitted to the FDA over the past seven years, and has been linked to at least 1,128 deaths.

Study: The Phase 3 clinical study, GIACTA, showed that serious adverse events occurred in 15% (roughly 1:7) patients using Actemra in the study.

Competing L-6 receptor inhibitors such as Humira, Enbrel, and Remicade, contain strong warnings against the above side effects. Actemra does not.

*Please call for criteria and pricing

BenicarManufacturers: Daiichi Sankyo, Forest LaboratoriesOther Drugs: Benicar HCT, Azor, Tribenzor

Issues/Injuries: Benicar is a prescription medication created for the treatment of high blood pressure. Patients who are taking Benicar have developed spur like enteropathy and are suffering from severe chronic diarrhea, nausea, vomiting, severe weight loss, and malnutrition.

Label Change: In July 2013 FDA required manufacturers to update warning labels in July of 2013, indicating for the first time that there was clear evidence the drugs may cause severe diarrhea problems.

MDL #2606: – District of New Jersey Judge Robert Kugler

Litigation Update: On August 1, 2017 there was an announcement that Daiichi Sankyo has offered to settle 2,300 Benicar claims for $300 million. Filing deadline has now passed for the settlement and this litigation is now closed.

Gadolinium Toxicity Manufacturers: GE Healthcare, Bracco Diagnostics, Mallinckrodt Inc, Berlex Labs, among others

Issues/ injuries: Gadolinium is used in contrast dyes during magnetic resonance imaging (MRI), used in approximately 30% of scans, and magnetic resonance angiography (MRA). Patients with pre-existing kidney conditions who receive a gadolinium-containing contrast agent during these scans are at risk for developing nephrogenic systemic fibrosis (MDL 1909 – resolved). New concerns regarding gadolinium is something known as gadolinium retention, gadolinium deposition disease, or gadolinium storage condition.

FDA Warning: September 2017, the Medical Imaging Drugs Advisory Committee (MIDAC) of the US Food and Drug Administration voted overwhelmingly to add more warnings to gadolinium-based contrast agents. These warnings will include the risk of gadolinium retention in a patient's body, including the brain.

Claims of Note: In November 2017 Chuck Norris and his wife filed suit against 11 pharmaceutical manufacturers and distributors over her being poisoned by gadolinium contrast agents (GCBA) she was injected with during MRI scans.


INVOKANA (canagliflozin)

Products: Invokana, Invokamet, Farxiga, Glyxambi, Jardiance, Xigduo XRManufacturers: Johnson & Johnson, Janssen Pharmaceuticals Inc., AstraZeneca, Boehringer IngelheimIssues/Injuries: Failed to warn patients and physicians of the increased risks of kidney failure, heart attacks, ketoacidosis and diabetic ketoacidosis (DKA), loss of bone density, and severe Urinary Tract Infections (UTIs) requiring hospitalization.5-15-15 FDA puts out a safety announcement that SGLT2 inhibitors may lead to ketoacidosis.5-18-17 FDA issues new Black Box warning in regards to increased risk of leg, foot, and toe amputations for Invokana, Invokamet, and Invkoamet XR 6-8-17 JAMA new study published in the New England Journal of Medicine shows that SGLT2 inhibitors appear to have double the risk for DKA when compared to DPP-4 inhibitors. MDL 2750 (Invokana): District of New Jersey, U.S. District Judge Brian R. Martinotti. MDL 2776 (Farxiga): Southern District of New York, U.S. District Judge Lorna G. Schofield*Invokana, Invokamet, Invokamet XR amputation claims are currently some of the most sought after claims in the industry.


Limbrel®

Manufacturer: Primus Pharmaceuticals

Issues/ injuries: The osteoarthritis drug, which ismarketed as a “medical food” that can manage the metabolic process associated with osteoarthritis (OA), has been linked to drug-induced liver damage, immunological complications and a severe lung condition called hypersensitivity pneumonitis.

FDA Warning: December 2017, FDA issued a Drug Safety Alert, indicating that it had advised Primus Pharmaceuticals to voluntarily recall Limbrel (which the manufacturer has not done) after an investigation determined it to be an “unapproved new drug.” Limbrel has been linked to over 200 adverse event reports.

No Current MDL: Limbrel is a brand new topic


Onglyza (Saxagliptin)

Manufacturers: Bristol-Myers Squibb, AstraZenecaOther Drugs: Kombiglyze XR

Issues/ injuries: Onglyza is a type 2 diabetic drug in a class known as DPP-4 Inhibitors which are used to control blood glucose levels in type 2 diabetes patients and has been linked to Congestive Heart Failure (CHF), myocardial infraction, stroke, unstable angina & heart failure as well as severe joint pain and pancreatitis and pancreatic cancer.

FDA Warnings: - February 2014 - FDA issued Safety Communication as a result of a New England Journal of Medicine study that reported patients are at an increased risk of heart attack while taking Saxagliptin. - April 2015 - The FDA’s Endocrinologic and Metabolic Advisory Committee voted 14-1 in favor of changing the drug’s label in light of results from a post-market study (SAVOR) that found Onglyza was associated with a 27% increase in hospitalization for heart failure, as well as a higher risk of all-cause mortality.- April 2016 - FDA ordered change in warning label to be updated to advise patients about the risk of heart failure after evaluating two large scale clinical trials for people with type 2 diabetes, which found that 3.5% of people taking Saxagliptin were hospitalized for heart failure. No Current MDL: On January 25, 2017 arguments will heard by the JPML panel in Miami regarding consolidation of Onglyza claims


OpioidsDistributors: McKesson Corp, Cardinal Health and AmerisourceBergen Drug Co.

Manufacturers: Endo, Janssen, Actavis, Teva, Perdue, and Mallinckrodt

Products: OxyContin, Roxicodone, Oxecta, Hydrocodone, Methadone, Fentanyl, Morphine

August 11, 2017: President Donald Trump declares opioid crisis a National Emergency

Issues: Attorney Generals from several states have initiated investigations or filed suit against manufacturers and distributors. In one example, the state of West Virginia saw more than 780 million opioid pills distributed to 1.8 million people between 2007 and 2012. The number of abusers, overdoses, and deaths has more than quintupled over the past decade.

MDL 179-03: A Motion to Transfer all actions filed by gov’t entities was filed September 25, 2017 with the requested jurisdictions either Southern District of Ohio or Southern District of Illinois. Perdue is said to be negotiating a global settlement with attorneys general from several states regarding relief for states and municipalities but not individual claimants.


PPI DRUGS(Proton Pump Inhibitors)Manufacturers: AstraZeneca, Pfizer, Proctor & Gamble, Takeda Pharmaceuticals, NavartisIncluded Drugs: Prilosec, Prevacid, Nexium, Dexilant, Protonix, AcipHex, Vimovo, Zegarid

A Stanford Medicine data mining study linked heartburn drugs to an increase risk of heart attack and Chronic Kidney Disease (CKD). PPIs have also been linked to acute kidney injuries, acute interstitial nephritis, and kidney or renal failure.

Researchers found that people who take the medication to suppress the release of stomach acid are 16 percent to 21 percent more likely to suffer myocardial infarction.

A new study published in the February 2016 issue of JAMA indicated a 20-50% increase in occurrence of CKD over baselines.

More than 100 million prescriptions filled annually in US.

Over 20 million users in the U.S., which is around one out of every 14 people.

PPI’s have global annual sales of over $14 Billion a annually.

MDL 2789 : District of New Jersey, Judge Claire C. Cecchi*January 2018 – CMO for PSC to file Master Complaint outlining all of the allegations against the manufacturers.


TasignaManufacturers: Novartis

Issues/ injuries: Tasigna, a Tyrosine Kinase Inhibitor (TKI) was developed to treat Chronic Myeloid Leukemia. Tasigna has been linked to severe atherosclerosis (an irreversible condition). The condition causes fibrofatty plaque and white blood cell build-up, narrowing arterial walls and subsequently reducing blood flow. The resulting arterial blockage can cause cardiovascular events such as heart attack, strokes and death.

No Label Warning: Tasigna does not warn for atherosclerosis. In April 2013, Heath Canada (Canadian equivalent to FDA) released a statement indicating a recent study found arterial blockage related injuries in up to 6% of patients and announced changes would be made to the warning label regarding potential the risk for atherosclerosis with Tasigna use.

Tasigna Settlement: In 2015 Novartis agreed to a settle a civil fraud case for $390 million with the Department of Justice over paying illegal kickbacks (which included further kickbacks via paid patient referrals and drug rebates) to promote the drug.


Taxotere (docataxel)

Manufacturer: Sanofi-Aventis

Issues/ injuries: Taxotere has been linked to a condition called alopecia, wherein a significant portion of the hair lost during chemotherapy treatments never grows back. Approximately 10-15% of women who took Taxotere during chemotherapy treatments for breast cancer have experienced alopecia.

FDA Waring: In December 2015 the FDA mandated an Adverse Reactions warning regarding cases of permanent alopecia (permanent hair loss)

MDL 2740: Eastern District of Louisiana, Judge Lance M. Africk. Settlement discussions are underway prior to the scheduling of the first bellwether. It is believed that these claims may possibly resolve before the first bellwether.


TRT (testosterone replacement therapy)

Manufacturer: AbbVie is the main defendant but other defendants are involved (Auxilium - Testim, and Eli Lilly – Axiron).

Brands: AndroGel, Androderm, Axiron, Fortesta, Striant, and Testim

Issue/ Injuries: Extremely popular prescribed testosterone medications, like AndroGel, have now been shown to cause strokes, pulmonary embolisms, heart attacks, DVT (Deep Vein Thrombosis), other associated serious blood clots, and death.

MDL 2545: Northern District of Illinois, Judge Matthew Kennelly *First bellwether trial (AndroGel) began June 5, 2017, declared a mistrial when a plaintiff attorney fell ill. Second bellwether trial resulted in a $150 million verdict for the plaintiff. On Sept. 11, 2017 there was a defense verdict in an IL state case. On October 3rd jury awarded plaintiff $140 million in second bellwether trial. Based on the results of these verdicts global settlement discussions with AbbVie are underway. First Testim trial, which concluded Nov. 16th, 2017, went in favor of the defense. The third Androgel bellwether is set for January 2018 as is the first Axiron bellwether. Eli Lilly is said to have engaged plaintiffs regarding a global settlement to resolve Axiron claims.


Xarelto (rivaroxaban)Pradaxa (dabigatran etexilate)Manufacturer: Xarelto - Janssen Pharmaceuticals Pradaxa – Boehringer Ingelheim

Issues/Injuries: Xarelto and Pradaxa are anticoagulants that are advertised as a better alternative to Warfarin because patients are not required to go into a clinic for regular blood testing, which has been found to not be responsible or safe. Another issue is the fact that there is no antidote to get the blood to clot if needed. The "no blood test" claim with the no reversal agent available exposes patients to a much greater risk of suffering from a severe and uncontrollable bleeding event. The injuries we are targeting included severe bleeding events, gastrointestinal bleeding, cerebral hemorrhaging and death. Pradaxa and Xarelto have been linked to over 370 deaths.

Pradaxa Settlement: Boehringer Ingelheim settled approximately 4,000 claims for $650 million in 2014.

MDL 2592 (Xarelto): Eastern District of Louisiana, Judge Eldon Fallon

Xarelto MDL Trial and Related News: Plaintiffs have lost the first three bellwether trials, due mainly to “learned Intermediary Doctrine Defense”. Trials are also moving forward in PA state court, the first of which was the first win for plaintiffs in November ($28 million verdict), but was overturned in January. Also in late November, a federal judge in Texas requested that the DOJ & FBI about allegations of improper contact with witnesses by J&J in cases involving Xarelto, DePuy Pinnacle hip, and Ethicon transvaginal mesh.


ZofranManufacturer: GlaxoSmithKline

Issue/ Injuries: Zofran is an anti-nausea medication approved by the FDA in 1991 to help cancer patients undergoing chemotherapy and radiation treatment and also post surgery patients. It was being promoted for off-label use for women suffering from morning sickness. In 2012, the U.S. Department of Justice sued Glaxo for fraud because it illegally promoted this drug for use in pregnant women. It won a settlement of $3 billion—the largest drug fraud settlement ever. There have been links to birth injury if Zofran is taken within the first trimester. Injuries include cleft lip, cleft palate, heart defects, atrial and septal defects & even deaths.

In August 2013, a historical cohort study involving more than 900,000 pregnancies found that Zofran double the risk of heart defects and could potentially be associated with a 30% increased risk of birth defects overall.

MDL 2657: District of Massachusetts, Judge F. Dennis Saylor


Attune Knee ImplantManufacturer: DePuy SynthesProducts: Attune KneeAlso being followed: Exactech – Optetrak, Arthex - IBalanceIssues/ injuries: More than 600,000 knee replacements are performed each year in the US. The DePuy Sythesis Attune knee, which has been available since 2011, AND been the most commonly utilized Total Knee Replacement (TKR) implant since 2013 and a high number of Adverse Event Reports have been submitted to the FDA with respect to early implant failure in the form of: instability and/or warmth or heat in the knee, unusual swelling, dislocation of misalignment of parts, loosening of the knee replacement parts, persistent pain, and fractures of the bones (typically the tibia) around the knee replacement.

DePuy: More than 1,400 reports of DePuy Attune Knee issues have been reported through its Manufacturer and User Facility Device Experience (MAUDE) system.Exactech: Since 2012, FDA has received large number of Adverse Event Reports over early implant failure of the Optetrak TKR, after which Exactech removed “finned” tibial tray design, replacing with new “fit” tibial tray. Arthex: Issues have been reported since 2014 and in February 2016, a recall was issued for some of the IBalance devices, indicating the device surface was smooth instead of textured, and as such, could result in a failure to bond and ultimately fail.


BAIR HUGGER FAW Blanket Manufacturer: Arizant Healthcare, subsidiary of 3M

Issues/Injuries: Periprosthetic Joint Infections (PJI). Serious joint infection which could lead to amputation of the limb.

This is a forced air warmer that has been linked to contamination of the surgery room which leads to the PJI.

Used in ~90 percent of all hip and knee surgeries. We recommend you go back through old hip and knee medical records (especially anesthesia reports) as you may already have claimants in inventory.

MDL 2666: US District Court of Minnesota Judge Joan N. Ericksen. Roughly 4,200 pending claims. First round of bellwethers will be ‘trial ready’ by April 2018.


Essure Manufacturer: Bayer

Issues/ injuries: Essure is a hysteroscopic sterilization procedure wherein a soft metal spring like device with synthetic fibers is implanted into the fallopian tubes. The device is known to cause chronic pelvic pain, ectopic pregnancies, severe migraines and allergic reactions, pelvic organ perforation, autoimmune responses, additional revision surgeries to remove the device or repair internal organs, and death

FDA Warning: On February 29, 2016 FDA announced new mandatory clinical study and on November 14, 2016 announced that it will require a new black box warning and a Patient Decision Checklist.

JCCP #4887: On October 3, 2016 it was ordered that all cases will be coordinated in Alameda County, California under Judge Winifred Y. Smith. Claims are also being filed in PA state court and leading firms are still accepting new claimants under tightened screening criteria.


Hernia Mesh

Manufacturers: Atrium, Ethicon, C.R. Bard, Medtronic, OthersProducts: C-Qur, Physiomesh, Proceed, Kugel, 3D Max, PerFix Plug, Sepramesh, Ventralex ST, Patrietex Composite, Surgipro, TIGR® MatrixIssues/ injuries: Ethicon Physiomesh was brought to market via the 510(k) process without any pre-market research. Atrium also brought their C-Qur mesh to market via 510(k). These products are constructed out of polypropylene with a coating gel of omega 3 fatty acids and have an extremely high rate of complications including abdominal pain, infection, allergic reactions, bowel adhesion, ulcer, organ perforation, seroma, mesh erosion, and revision surgery. FDA Notice: Ethicon Physiomesh® was voluntarily pulled from the market in May 2016 and an “Urgent Field Safety Notice” was released following an FDA article after data was provided by HerniaMed German Registry and the Danish Hernia Base showed high rates of complications, hernia recurrences and revision surgeries.MDL #2753: Atrium C Qur US District Court of New Hampshire Judge Landya B. McCafferty.MDL #2782: Ethicon Physiomesh Northern District of Georgia Judge Richard W. Story


IVC FilterManufacturers: CR Bard, Cook Medical Issues: The device was meant to be put into patients if they have a serious risk of thrombotic event. The IVC Filter is not meant to be left in for a long period of time. Fractures, migration and perforation are much more likely if the device is left in more than 6 months.

Injuries: –Migration- The device migrates outside the inferior vena cava and into the body. –Fractures- Legs on the device fracture and break, then migrate to the body. –Perforation- device legs puncher the wall of the vein.

MDL #2570: Cook Medical Southern District of Indiana, Judge Richard Young MDL #2641: Bard District of Arizona, Judge Campbell Related News: On November 22, 2017 Bard IVC filter claims survive summary judgement.On November 9, 2017 the first Cook bellwether went to the defense.


LFIT V40 Metal Hips

Manufacturer: Stryker

Issues/ injuries: The Stryker LFIT V40 Anatomic CoCr Femoral Head, made from cobalt and chromium, which are known to be prone to corrosion and wear have been shown to cause two serious complications, Taper lock failure and metallosis. This can result in pain, loss of mobility, inflammation, dislocation, joint instability, broken bones around components, Chromium and Cobalt toxicity/poisoning and revision surgeries.

Recall: On August 29, 2016 Stryker announced a voluntary recall of 45,500 LFIT V40 femoral head manufactured between 2002 and 2011. Canadian government has issued a formal government recall and Australia has issued a “hazard alert” for the Stryker LFIT femoral head.

MDL 2768: District of Massachusetts, U.S. District Judge Indira TalwaniMCL 624: Bergen County, NJ, NJ Superior Court Judge Rachelle Harz

*In other related news: DePuy Pinnacle Hip MDL, another massive verdict went to the plaintiffs in the latest bellwether trial, wherein 6 plaintiffs were awarded a total of $247 million in damages, the third significant award to plaintiffs. J&J previously agreed to pay more than $2.4 billion to settle DePuy ASR metal hip lawsuits.


Mirena -PSEUDOTUMOR CEREBRIManufacturer: Bayer

Issues/Injuries: Women who are taking these birth control medications may be at risk of developing Pseudotumor cerebri (PTC). Pseudotumor cerebri literally means "false brain tumor". People with PTC have an increased amount of cerebral spinal fluid which causes pressure in the skull. This causes people to have similar symptoms to those who have brain tumors. In some cases it can cause progressively worsening vision and may eventually cause blindness if not treated.

Even if symptoms have resolved, they can recur months or even years later.

Serious injuries include vision loss, papilledema, and debilitating migraines which may require numerous lumbar punctures and shunts placed in the brain.

MDL 2767: Southern District of New York, Judge Paul Engelmayer *Two cases that were consolidated under Judge Stephen Bough, survived Daubert on December 22, 2016 in the Western District of MO will move forward separately. MDL Daubert hearing scheduled for April 2018. There is a belief that these claims may settle before bellwether trails.


Smith & Nephew Birmingham Hip

Manufacturer: Smith & Nephew

Issues/ injuries: The Birmingham Hip Resurfacing (“BHR”) System and R3 metal-on-metal liner are known to have caused high toxic levels of cobalt and chromium in patients implanted with the device, causing pain, adverse local tissue reaction, pseudotumor, bone and tissue necrosis, metallosis, and other symptoms requiring revision surgery.

Recall Notice: Smith & Nephew voluntarily recalled the R3 in June of 2012 due to abnormally high failure rates.

April 29, 2015 Urgent Field Safety Notice: Smith & Nephew issues notice stating that women and men over 65 who require an implant less than or equal to 48mm are more likely to require a revision surgery.

June 2015 Withdrawal from Market: Smith & Nephew withdrew the BHR device from the US market due to high failure rates.

MDL #2775: US District Court of Maryland, Judge Catherine C. Blake


Breast Implant ALCL

Food and Drug Administration reports breast implants have been linked to a rare form of cancer known as Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA – ALCL). FDA has reported nine deaths associated with BIA-ALCL.

This rare form of cancer is associated with both saline and silicone breast implants. It is believed that more than 300,000 breast implant procedures are performed in the US annually.

March 31, 2017 – FDA Issued update stating that they have received 359 medical device reports, including the nine deaths, associated with BIA-ALCL cancer of the immune system.


Roundup (glyphosate)

Manufacturer: Monsanto

Issues/ injuries: Roundup weed killer has been listed by the World Health Organization (WHO) as a probable human carcinogen. Farmers and farmhands living near and working around glyphosate products have a significantly increased risk of developing non-Hodgkin lymphoma and other forms of cancer.

March 2015 WHO: studies by the WHO and IARC (International Agency for Research on Cancer) and published in The Lancet Oncology, showed a link between glyphosate and non-Hodgkin lymphoma. It is believed that Monsanto has long known of and downplayed the cancer risk associated with Roundup exposure.

May 2017 EPA: Arthur A Elkins, Inspector General of EPA sends letter to Congressman Ted W. Lieu (D-CA) to confirm investigation launched into agency’s reviews of glyphosate and the side effects of Roundup.

June 2017 ECI: European Citizens Initiative announces they have gathered more than 1 million signatures calling for ban on all glyphospate-based pesticides, which will force the European Union Commission to issue a formal response.

MDL 2471: Northern District of California, Judge Vince Chhabria June 2018 trial date set for first state court trial (California)


Manufacturer: Sorin Group, LivaNova PLC

Issues/Injuries: Cardiac surgery infections. A growing number of adverse event reports are being filed blaming contaminated 3T units for patients developing nontuberculous mycobacteria (NTM) infections, namely M. chimaera, M. abscesses, and M. fortuitum.

Safety Notice & FDA Warning: In June 2015, LivaNova issued a Field Safety Notice to clients on how to use and clean the units. Six months later the FDA sent a warning letter to LivaNova after inspecting facilities in Munich and Arvada, CO, wherein the FDA found several violations including failure to adequately validate and verify procedures for cleaning and disinfecting the 3T Heater/Cooler machines.

MDL 2772: Petition filed January 26, 2017 by plaintiff requests lawsuits be centralized in US District Court of South Carolina under Judge Bruce H. Hendricks. On April 10, 2017, the Panel rejected the plaintiffs motion citing informal coordination is already taking place. In recent news, on November 6, 2017 the defendants requested centralization under Judge Hendricks. Arguments for consolidation are scheduled for January 2018 JPML hearing in Miami.

Suit seeking Class Action filed in US District Court of Iowa on May 31, 2017 involving punitive classes of asymptomatic plaintiffs that do not claim NTM infection, and instead seek relief only for the cost of medical monitoring for the potential development of an NTM infection.

Stöckert 3T Heater/Cooler


Talcum PowderManufacturer: Johnson and Johnson

Issues/ Injuries: A Sioux Falls, SD federal jury in 2013 found that J&J’s talc powder was the cause for the development of a women’s ovarian cancer. Studies showing a higher rate of the disease with talc use have typically found an increased risk of about 35 percent -- which would put the odds at about one in 50. New information is trying to establish a potential link to mesothelioma via talc mined containing tremolite.

MDL 2838: Oct. 5, 2016 MDL Centralized in New Jersey Federal Court under Judge Freda L. Wolfson.

Recent Trial Awards & News: August 20, 2017 $417 million verdict in California (later reversed). Several cases have been consolidated in front of a 3 judge panel in St. Louis, MO including recent jury awards for plaintiffs of $110 million, $72 million (later reversed), $70 million and $55 million. In May 2017, plaintiff verdict for $13 million was handed down over asbestos exposure, and in November 2017, Colgate-Palmolive settled another (the 43rd such) talc related mesothelioma lawsuit. A J&J meso trial in Los Angeles went to the defense on Nov., 16, 2017.


Contact InformationWe are currently generating quality leads through multimedia campaigns, as well as qualifying and signing claimants on behalf of our partnering firms. Please contact me today to discuss current pricing and lead or co-counsel options today!

Ethan HeckDirector of Business Development

Schmidt National Law GroupOffice: (800) 631-5656Direct: (858) 354-6393

[email protected]

As a marketing-focused law firm, Schmidt National Law Group handles all aspects of the front end of legal case work, including marketing, lead generation, full intake, and retention (signed retainers and HIPAA). Schmidt National Law Group has been involved in lead generation, case acquisition and co-counsel for pharmaceutical and medical device product liability claims for the past 20 years. Our firm prides itself on being the most transparent in the industry.

february 2018 mass tort topics of interest · 2018-04-04 · benicar 5 taxotere 13 essure 19...

Documents